Singapore S*BIO Licenses Leukemia Agent SB1317 To U.S.-Based Tragara

PERTH, Australia - Just two weeks after announcing a development collaboration deal with Onyx Pharmaceuticals on JAK2 inhibitors, Singapore-based S*BIO announced it inked a licensing deal Jan. 21 with San Diego-based Tragara Pharmaceuticals covering its multi-kinase inhibitor SB1317 for leukemia